SG Americas Securities LLC boosted its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 1,158.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 525,421 shares of the company's stock after buying an additional 483,675 shares during the period. SG Americas Securities LLC owned 0.41% of Organogenesis worth $2,270,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also bought and sold shares of ORGO. Merit Financial Group LLC purchased a new stake in shares of Organogenesis during the 1st quarter worth $45,000. Wellington Management Group LLP raised its holdings in Organogenesis by 5.2% in the fourth quarter. Wellington Management Group LLP now owns 254,282 shares of the company's stock worth $814,000 after purchasing an additional 12,634 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Organogenesis by 16.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 39,159 shares of the company's stock valued at $125,000 after buying an additional 5,551 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Organogenesis by 255.1% in the 4th quarter. Mackenzie Financial Corp now owns 76,353 shares of the company's stock valued at $244,000 after buying an additional 54,850 shares in the last quarter. Finally, Soleus Capital Management L.P. grew its position in shares of Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock worth $39,952,000 after buying an additional 645,000 shares during the last quarter. Institutional investors own 49.57% of the company's stock.
Wall Street Analyst Weigh In
Separately, Morgan Stanley lifted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th.
View Our Latest Research Report on Organogenesis
Organogenesis Price Performance
Organogenesis stock traded up $0.13 during midday trading on Wednesday, reaching $3.26. The company's stock had a trading volume of 340,198 shares, compared to its average volume of 1,146,068. The stock has a market capitalization of $413.15 million, a P/E ratio of -19.09 and a beta of 1.63. The stock's 50-day simple moving average is $3.73 and its 200-day simple moving average is $3.82. Organogenesis has a 52-week low of $2.28 and a 52-week high of $6.71.
Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). The company had revenue of $86.69 million during the quarter, compared to analysts' expectations of $90.77 million. Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. As a group, equities research analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Lori Freedman purchased 9,022 shares of Organogenesis stock in a transaction that occurred on Friday, June 6th. The stock was bought at an average cost of $2.99 per share, for a total transaction of $26,975.78. Following the completion of the transaction, the insider now owns 846,459 shares in the company, valued at $2,530,912.41. The trade was a 1.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have purchased 252,264 shares of company stock valued at $725,732 over the last ninety days. 33.00% of the stock is currently owned by insiders.
Organogenesis Profile
(
Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Read More
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
